Subscribe to enjoy similar stories. Tata Capital Healthcare Fund (TCHF) is planning to increase the ticket size of each of its investments to around $25 million, from $10-18 million currently, the private equity (PE) fund’s managing partner Visalakshi Chandramouli said, as demand for healthcare in the world's fifth-largest economy grows. The fund is also betting on domestic pharmaceutical companies that target global markets.
The healthcare and life sciences-focused PE fund has raised a total $200 million across its two funds - TCHF I (2012) and TCHF II (2022). So far, it has deployed 90% of its $130 million second fund corpus. TCHF II has so far invested in nine companies across diverse segments of the healthcare sector, and is in the process of concluding a tenth investment in the medical consumables segment, Chandramouli told Mint.
“This is a business where the macro theme is essentially the India indigenization story, where we are looking at local production for global products," Chandramouli said, adding that local players for global markets is a big shift happening in the medical technology space in India. “This is a company which is a leader in the select medical consumables category, having a very strong regulatory know-how, exports to over 50 countries, and reasonable growth as well as profitability," she said. Chandramouli declined to name the company or share more details, but said they plan to conclude the investment soon.
Read more on livemint.com